Fig. 3

Effects of KYA1797K on the CSC properties of mice harboring Apc and Kras mutations. Analysis of 5-week-old Apc^Min/+/K-ras^G12DLA2 mice treated with intraperitoneal (i.p.) injections of vehicle or KYA1797K (25 mg/kg) 5 days per week for 7 weeks (N = 4). a Immunoblots of vehicle- or KYA1797K-treated small intestinal tumors of Apc^Min/+/K-ras^G12DLA2 mice using the indicated antibodies. b, c The numbers (b) and sizes (c) of vehicle- or KYA1797K-treated small intestinal tumors of Apc^Min/+/K-ras^G12DLA2 mice. d IHC analyses of small intestinal tumors treated with vehicle or KYA1797K using the indicated antibodies. Representative images were captured using Zeiss confocal microscope from at least three different fields. Boxes indicate enlarged areas. Scale bar in the low-magnification images represents 20 μm, and the scale bar in the high-magnification images represent 100 μm. e Bright-field microscopy images of DMSO- or KYA1797K-treated tumor organoids derived from small intestinal tumor cells after 0, 3, 5, and 7 days. Representative images were captured using a Nikon 2000 U microscope from three different fields. f Viable cells were detected by luminescence production using CellTiter-Glo® Luminescent Cell Viability Assay. g Numbers and sizes of tumor organoids were measured using Image J v1.47 software. The quantitative data are presented as mean ± standard deviation. ** P < 0.01, *** P < 0.001